Özet:

By the end of 2019, a new coronavirus was detected in the Chinese state of Wuhan, which caused acute respiratory failure syndrome in patients. This virus was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Virus Taxonomy Committee. The new coronavirus disease was named coronavirus disease 2019 (COVID-19) by the World Health Organization. This virus has been found to be in the underclass of Betakoronavirus caused by wounds. The role of viral proteins in immunopathogenesis, such as cover, membrane, nucleocapsides and spike proteins, responsible for viral infection, is studied in studies. Especially in advanced stages of the disease, it has been emphasized in studies in which multiple organ deficiencies associated with the development of the cytokine storm have developed. The effective host immunity response, including natural and adaptive immunity to SARS-CoV-2, is essential for controlling and treating viral infection. Although there is no effective treatment for the disease today, studies have shown the benefits of some medications with a variety of immunosuppressive and immunomodulating properties. In this article, the immunopathogesis of SARS-CoV-2 and the treatments that may be effective through it have been reviewed in the accompanying current literature.